AEON Biopharma, Inc. - AEON STOCK NEWS

Welcome to our dedicated page for AEON Biopharma news (Ticker: AEON), a resource for investors and traders seeking the latest updates and insights on AEON Biopharma stock.

AEON Biopharma, Inc. (symbol: AEON) is a clinical-stage biopharmaceutical company focused on the development of its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, targeting multiple debilitating medical conditions. The company initially concentrates on the neurosciences market and aims to leverage ABP-450 in treating conditions such as cervical dystonia, migraine, and potentially post-traumatic stress disorder (PTSD). This biopharmaceutical entity was listed on the NYSE following a merger with a special purpose acquisition company (SPAC) designed to merge with healthcare-related businesses.

Recent developments include positive data from the 52-week open-label extension (OLE) Phase 2 study of ABP-450 in treating cervical dystonia, showing peak efficacy within four weeks and a durability of effect between 12 to 16 weeks post-treatment. AEON also presented pre-clinical data at the TOXINS 2024 conference highlighting the promising results of ABP-450 in conjunction with lidocaine for treating PTSD in a rat model via image-guided Stellate Ganglion Block (SGB).

Financially, AEON recently closed a $15 million Private Placement with Daewoong Pharmaceutical, bolstering its resources for further clinical development of ABP-450. Despite a recent interim analysis from the Phase 2 chronic migraine study not achieving its primary endpoint, the company remains optimistic about advancing other late-stage programs such as cervical dystonia and gastroparesis.

ABP-450 is manufactured under stringent guidelines by Daewoong, ensuring compliance with regulatory standards including cGMP. AEON holds exclusive rights for ABP-450's therapeutic applications across key territories including the USA, Canada, and the EU.

Management Team: AEON's leadership includes highly experienced professionals, with Marc Forth serving as President and CEO, alongside other key figures like Dr. Chad Oh and Chief Financial Officer Jennifer Sy. Their combined expertise is instrumental in navigating the company through its clinical milestones and regulatory approvals.